Keybanc analyst Paul Knight maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $440 to $470.
Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $470
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.